Fig. 7: Nucleocapsid Protein (Np) IgG titers. | npj Vaccines

Fig. 7: Nucleocapsid Protein (Np) IgG titers.

From: Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine

Fig. 7

Serum samples were obtained from 70 subjects on days 0, 28, 56, 90, 180, and 273 after receiving a 90 µg s.c. dose of AKS-452 administered ≥3 months after completion of regulatory–approved vaccinations and assessed for anti-Np IgG binding titers via ELISA of which a positive cut-off was 0.5 µg/mL, dotted line (geometric mean ± s.e.m.). *, p < 0.05; geometric mean values were significantly different from the respective day-0 values (t test, equal variance, one-tailed). ** N = 71 subjects (includes 1 dropout subject).

Back to article page